e-therapeutics has announced an agreement to work on a neurodegeneration project with a top 5 global pharmaceutical company. We believe the agreement is with MSD, the ex-US businesses of Merck & Co Inc, but this has not been confirmed. The 12-month agreement employs the NDD platform to target the discovery of novel biological mechanisms and therapeutic approaches for neurodegenerative diseases, such as Alzheimer’s and Huntington’s.
13 Aug 2019
Second agreement helps validate capabilities
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Second agreement helps validate capabilities
e-Therapeutics plc (ETX:LON) | 9.5 0 1.7% | Mkt Cap: 55.4m
- Published:
13 Aug 2019 -
Author:
Mick Cooper PhD -
Pages:
2
e-therapeutics has announced an agreement to work on a neurodegeneration project with a top 5 global pharmaceutical company. We believe the agreement is with MSD, the ex-US businesses of Merck & Co Inc, but this has not been confirmed. The 12-month agreement employs the NDD platform to target the discovery of novel biological mechanisms and therapeutic approaches for neurodegenerative diseases, such as Alzheimer’s and Huntington’s.